QuidelOrtho
QuidelOrtho is seeking a Scientist I to join the Troubleshooting department as part of an 18-month fixed-term contract. The role involves interpreting scientific data, conducting root cause investigations on product non-conformances, and ensuring compliance with global quality and safety systems. This position offers exposure to R&D operations and cross-functional collaboration within a state-of-the-art manufacturing facility in Pencoed.
QuidelOrtho is a global diagnostics company that provides vital health information across the entire healthcare continuum, from home to hospital and lab to clinic. The company offers a broad portfolio of diagnostic solutions including point-of-care rapid tests, immunohematology systems, molecular diagnostics platforms, clinical chemistry and immunoassay analyzers, and lab management software. QuidelOrtho's products — such as the VITROS™, SOFIA™, ORTHO VISION™, and QUICKVUE™ lines — are designed to deliver fast, accurate, and actionable results to improve patient care, safety, and treatment decisions.
Michael Iskra Appointed CEO of Cleveland Diagnostics to Drive Strategic & Accelerated Growth Following FDA Approval of Its IsoPSA Assay
1 month ago
Cleveland Diagnostics Names New CEO Following FDA Approval of Prostate Cancer Test
1 month ago
Cleveland Diagnostics names new CEO
1 month ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for QuidelOrtho.
QuidelOrtho didn’t post a salary, so this is our estimate from similar listings.
352% above the average for this role
Lab Automation Market Industry Trends and Global Forecasts to 2035, with Profiles of Abbott, Anton Paar, ERWEKA, Leuze, Ortho Clinical Diagnostics, Pall, PerkinElmer, Roche Diagnostics, SYSTAG & More
Sep 24, 2025